Pharmacogenomics combines clinical information with knowledge about the human or pathogen genome for the purpose of clinical development. It facilitates the discovery of new targeted drug and gene therapies that have fewer side effects, higher efficiency, and at reduced costs. In addition, it can be used to identify potential clinical trial subjects more effectively, and improve the costly and time-consuming process of patient recruitment.
The implementation of Pharmacogenomics is based on biomedical information integration (MedII) technology, that can standardize, de-identify, integrate, and correlate clinical trials with genomic and image metadata which are described in diverse formats and vocabularies and scattered in disparate islands of data. The data is then also integrated with public data sources such as PubMed and GenBank. Biomedical information integration technology is vital in the various clinical trials phases, in the submission process to the regulatory authorities such as the FDA as well as in the post drug development phase, by finding implications that are deduced from a large scale usage of the drug, or when drug resistance is encountered.
Pharmacogenomics Example - EuResist
EuResist, a pharmacogenomics project, integrates viral genomics with clinical data in order to predict responses to anti-HIV treatment. The EuResist project aims at developing a European integrated system for clinical management of antiretroviral drug resistance. The system will provide clinicians with a prediction of response to antiretroviral treatment in HIV patients, thus helping them choose the best drugs and drug combinations for any given HIV genetic variant. To this end, The Haifa MedII technology will be used to generate a huge European integrated data set, linking some of the largest existing resistance databases.